ProCE Banner Activity

Phase II GEM-CESAR: Post Hoc Analyses of Sustained uMRD at 4 Yr After KRd + ASCT for High-Risk MM

Slideset Download
Conference Coverage

Potentially curative therapy with KRd followed by ASCT, KRd consolidation, and lenalidomide maintenance in high-risk smoldering MM is encouraging, with 43% of patients MRD negative at 4 years and only 6% progressing to active MM.

Released: December 13, 2022

Expiration: December 12, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen